Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Plans To Upgrade Recalled OTCs for Relaunch

This article was originally published in The Tan Sheet

Executive Summary

Johnson & Johnson plans to return recalled OTC drugs to the market with innovations designed to strengthen consumer trust, VP of Finance and CFO Dominic Caruso said during a presentation at the Deutsche Bank Securities Health Care Conference.
Advertisement

Related Content

OTC Industry Standardizes Pediatric Liquid Acetaminophen Concentration
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
FDA Enforces Consent Decree Over J&J/McNeil's OTC Manufacturing
McNeil OTC Recalls Slice $900M From J&J's 2010 Sales
Advertisement
UsernamePublicRestriction

Register

PS105033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel